Africa New Energies holds an oil exploration license in Namibia, where it has applied its unique surface exploration method to identify a gross unrisked prospective resource of 1.6 billion barrels of oil equivalent.
days to go:
Expired
investment:
Withheld
Pass the Keys is a leading short-let tech platform operating in 20 cities across the UK. Till date, the company has hosted 30,000+ guests and earned £15 million for its hosts. The company lists a landlord's property on appropriate portals, finds relevant guests for an event or function, looks after their needs, and even takes care of cleaning up the venue after an event. The company's end-to-end technology automates the majority of the tasks such as job scheduling, invoicing, calendar syncing, and pricing with reliable support staff ready to assist with any eventuality. The company has achieved good ratings on Google reviews, Trustpilot and Glassdoor. The company will use 50% of the investment to expand its franchise, 30% for product development, and 20% for training personnel and supporting infrastructure.
days to go:
Expired
investment:
£1,069,632
Belluscura aims at attending millions of people worldwide who are suffering from chronic lung diseases by providing them with the X-PLOR, portable, a lightweight, oxygen delivery device. It has developed it mainly to improve both the mobility and the life quality of the patients suffering from Chronic Obstructive Pulmonary Disease globally. It also has an exclusive license to a patented portable oxygen concentrator, the X-PLOR, that supplies 96% pure oxygen to patients 24/7. It's X-PLOR weights only 1.4kg and is 33% lighter, and provides 37% more oxygen per kg than its leading opponents. As smoke, pollution, and lives increase, the oxygen market will continue to grow from £1.1bn to £1.9bn by 2024. So, according to its market research, a 3% market share within 3 years could generate £46m in sales. With the funds raised, it is planning to extend its proprietary oxygen platform technology into other multi £bn markets such as wound care and sleep. Furthermore, it has filed patents on a next-generation portable artificial lung.
days to go:
Expired
investment:
£543,670
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go:
Expired
investment:
£451,506
An easy and simple app for university students to find properties and pay rent all from the comfort of their own sofa. Bubble Student already has information for over 200,000 rooms, which users can book viewing schedules for, as well as a group chat feature to easily discuss the property with their friends.
days to go:
Expired
investment:
£430,320
Carnot is developing hydrogen engines with key components manufactured from ceramics able to withstand fuel combustion temperatures, eliminating the need for cooling systems and doubling the efficiencies of modern engines. The company argues that modern engines waste on average one-third of fuel energy to cool systems that stop metallic components from melting. Carnot claims that its engines eliminate this waste doubling efficiency, halve fuel costs and CO2 and achieve net-zero operation by operating on biofuels and hydrogen benefiting the long haul transport, marine and primary off-grid power markets. Carnot has raised over £600,000 including a pre-seed round in 2020 for £357,000 at a pre-money valuation of £2 million, a £300,000 Innovate UK grant and another £300,000 Eureka Eurostar’s grant. Carnot has a 5-year, 3-phase exit strategy and will begin licensing its IP at the end of 2023 at which point it will begin generating revenue. It will eventually look for acquisition from one of its manufacturing partners in 2025 after demonstrating industry acceptance of its technology.
days to go:
Expired
investment:
£262,500
Reducing the cost of orthopaedic equipment by using compression screws and titanium maxiangle locking plates. DC Surgical Supplies have acquired an exclusive license with Palmer & Baker with the aim of helping the NHS cut the cost of purchasing regular-use equipment by as much as 35%. Their product is CE Certified and has been featured in The Telegraph.
days to go:
Expired
investment:
£99,000
Providing dental professionals with an online Personal Development Plan for their Continuing Professional Development. Dentinal Tubules currently has more than 2,100 individuals registered to use the service and over 2,700 dental practice professionals that are paying for a subscription.
Dentinal Tubules hosts more than 1,500 educational and certified videos to help with a professional's CPD, in addition they also offer live courses, a livestream and an annual congress. Investments will be used to enhance, develop and bring the technology in-house.
days to go:
Expired
investment:
£155,820
CoreHaus applies known, tried and tested construction methodology intelligently to meet the growing demand for offsite manufactured housing solutions. Their principles are based on ground and the first floor standardised 'modular cores' which includes a pre-finished kitchen, staircase, central heating and electrical control systems and bathroom. Their product has designed and developed, trademarks and IP's are in place, private sites secured under contract, and they are currently working with some exciting partners and supply chains to roll out the product launch.
days to go:
Expired
investment:
Withheld
Improving the railway construction industry by collecting data to reduce inefficiencies and overspending. Rail Diary is a B2B SaaS product that is designed to analyse information on infrastructure projects to improve particular elements that plague the industry. These include the delivery, commercialisation and the health and safety of projects.
Rail Diary allows developers to monitor ongoing costs, forecast for the future and reduce the number of claims made. Rail Diary will generate revenue via a monthly subscription model ranging from £45 to £150, plus project fees.
days to go:
Expired
investment:
£50,544
